

## Thursday 2<sup>nd</sup> February 2012 (morning)

| Time  | Speaker  | Title   |
|---|--|---|
| 8:00-8:15   | <b>Opening Words and welcome address: Edoardo Camenzind</b>  |   |
| 8:15-8:30   | <b>Opening speech:<br/>To the 100th anniversary of the Nobel prize of Alexis Carrel : the man and his accomplishments Thierry Carrel</b> |   |
| <b>The aortic valve: <i>part I</i>: from experimental models to pathogenesis of aortic stenosis</b> |  |   |
| <b>Chairpersons: G.Gabbiani T.Carrel T.Gherli</b>   |  |   |
| 8:30-8:45   | <b>Stanton Rowe</b>  | Experimental animal models to evaluate biological valves  |
| 8:55-9:08   | <b>Ludwig von Segesser</b>   | Clinical surgical experience with stented and stentless bioprosthetic valves  |
| 9:16-9:29   | <b>Gaetano Thiene</b>  | Stented and stent-less bioprosthetic valves: graft- and patient-related factors influencing durability  |
| 9:37-9:50   | <b>Cathy Shanahan</b>  | Mechanism of vascular and tissular calcification  |
| <b>COFFEE 10:00-10:30</b>   |  |   |
| <b>The aortic valve: <i>part II</i>: from engineering to clinics</b>                                |  |   |
| <b>Chairpersons: L.von Segesser O.Wendler G.Thiene</b>  |  |   |
| 10:30-11:07<br>10:30-10:45  | <b>Netanel Benichou</b>  | The impact of a TAVI frame and valve design on long-term durability as assessed by bench, animal and clinical testing: Edwards' experience    |
| 10:45-10:57   | <b>Olaf Wendler</b>  | The Edwards-Sapien <sup>TM</sup> clinical program (Edwards)   |
| 11:07-11:45<br>11:07-11:22  | <b>Eric Richardson</b>   | The impact of a TAVI frame and valve design on long-term durability as assessed by bench, animal and clinical testing: Medtronic's experience |
| 11:22-11:34   | <b>Johan Bosmans</b>   | The CoreValve <sup>TM</sup> clinical program (Medtronic)  |
| 11:45-12:00   | <b>Hans-Reiner Figulla</b>   | From the idea to the product: the JenaValve <sup>TM</sup> System (JenaValveTechnology)  |
| 12:10-12:25   | <b>Gaetano Thiene</b>  | Structural deterioration in TAVI and sutureless valves and potential implications on durability   |
| 12:35-12:50   | <b>Robert Matheny</b>  | A novel concept of biological valve: from bench to in animal- and FIM results (Cormatrix)   |
| <b>LUNCH 13:00-14:00</b>  |  |   |

## Thursday 2<sup>nd</sup> February 2012 (afternoon)

| Time   | Speaker                       | Title   |
|--|-------------------------------|---|
| <b>The aortic valve: <i>part III</i>: TAVI and improvement deserving complications</b> |                               |   |
| <b>Chairpersons: E.Grube J.Bosman T.Gherli</b>   |                               |   |
| 14:15-14:30  | <b>Johan Bosman</b>           | Improvement deserving TAVI related complications  |
| 14:40-14:52  | <b>Cristina Basso</b>         | Interventional anatomy and pathology of TAVI  |
| 15:02-15:14  | <b>Philipp Kahlert</b>        | Incidence and mechanisms of cerebral micro-embolization during TAVI   |
| 15:24-15:36  | <b>Eberhard Grube</b>         | Clinical experience with cerebral protection systems during TAVI  |
| 15:46-15:58  | <b>Ron Nitzan</b>             | Desirable properties for next generation cerebro-protection devices: development guiding considerations and technical challenges                    |
| 16:08-16:20  | <b>Juan Badimon</b>           | Speculations on the best long-term anti-thrombotic therapy after TAVI   |
| <b>TEA 16:30-17:00</b>   |                               |   |
| <b>The unstable plaque: Pathology, patho-physiology and treatment</b>                  |                               |   |
| <b>Chairpersons: G.Gabbiani J.Badimon F.Crea</b>                                       |                               |   |
| 17:00-17:20  | <b>Göran Hansson</b>          | <u>State of the art</u> : Stable and unstable plaque from animal models to human disease  |
| 17:30-17:45  | <b>Koen Nieman</b>            | Non-invasive plaque imaging in 2012   |
| 17:55-18:10  | <b>Antonius Van Der Steen</b> | Invasive plaque imaging in human: intravascular optical and acoustical imaging of atherosclerosis (IVUS, OCT and infrared transmission technology)  |
| 18:20-18:35  | <b>Filippo Crea</b>           | Importance of the role of inflammatory markers in athero-thrombotic disease and the failure of chronic anti-inflammatory treatment: an anti-thesis? |
| 18:45-19:00  | <b>Ludovic Drouet</b>         | Differences among oral ADP inhibitors   |
| 19:10-19:25  | <b>Juan Badimon</b>           | Pharmacological differences among ADP inhibitors can they explain the differences in clinical outcomes ?  |
| 19:35-19:50  | <b>Douglas Greene</b>         | Treating beyond the athero-thrombotic plaque for myocardial salvage   |
| <b>20:00 - Buffet Dinner</b>   |                               |   |

## Friday 3<sup>rd</sup> February 2012 (morning)

| Time  | Speakers                   | Title  |
|---|----------------------------|--|
| <b>From bench to clinics: The endothelium</b>               |                            |  |
| <b>Chairpersons: M.L.Bochaton M.Flugelman H.VanBeusekom</b> |                            |  |
| 08:00-08:15   | <b>Heleen Van Beusekom</b> | Interspecies comparison of endothelial cells   |
| 08:25-08:40   | <b>Jaipal Singh</b>        | Improvement of re-endothelialization by surface nano-patterning  |
| 08:50-09:05   | <b>Moshe Flugelman</b>     | Re-endothelialization modulation as obtained in experimental work on vascular grafts   |
| 09:15-09:30   | <b>Nicolas Foin</b>        | Flow related healing response and re-endothelialization pattern in animal models   |
| 09:40-09:55   | <b>Justin Davies</b>       | Functional versus morphological evaluation of arterial stenosis  |
| <b>COFFEE 10:05-10:30</b>                                   |                            |  |
| <b>GUIDED POSTER PRESENTATION</b>                           |                            |  |
| <b>From bench to clinics: renal denervation</b>             |                            |  |
| <b>Chairpersons: J.Bohlender JP Singh F.Mahfoud</b>         |                            |  |
| 10:30-10:45   | <b>Juergen Bohlender</b>   | Pathophysiology of hypertension: focus on role and function of the sympathetic system in bloodpressure homeostasis   |
| 10:55-11:05   | <b>Guy Leclerc</b>         | Renal denervation strategies: experimental work using an internal thermal denervation  |
| 11:15-11:30   | <b>Christopher Owens</b>   | Renal denervation strategies: adventitia as a drug delivery target for chemical renal denervation: lessons from preclinical and early-phase clinical studies |
| 11:40-11:55   | <b>Felix Mahfoud</b>       | Clinical experience with radiofrequency ablation for the treatment of hypertension   |
| 12:05-12:20   | <b>Stephen Ruble</b>       | Alternative device strategies: Vagal stimulation   |
| <b>LUNCH 12:30-13:30</b>                                    |                            |  |

## Friday 3<sup>rd</sup> February 2012 (afternoon)

| Time  | Speakers                  | Title   |
|---|---------------------------|---|
| <b>Biodegradable stent: current experience and innovation in perspective</b>    |                           |   |
| <b>Chairpersons: R.Virmani A.Lafont G.Kaluza</b>                                |                           |   |
| 13:45-13:57   | <b>Stefano Mischler</b>   | An introduction to corrosion of biomedical alloys and its impact on implant stability   |
| 14:07-14:19   | <b>Boris Warnack</b>      | Bioabsorbable magnesium scaffold: novel experimental results and clinical results (Biotronik DREAMS program)                                    |
| 14:29-14:41   | <b>Greg Kaluza</b>        | Bioresorbable scaffold: in animal evaluation of REVA using multimodality imaging and long-term results (REVA program)                           |
| 14:51-15:03   | <b>Antoine Lafont</b>     | Biodegradable stent: comparing different iterations in different animal models (rabbit and pig) at different time points (ART)                  |
| 15:13-15:25   | <b>Richard Rapoza</b>     | Long-term experimental data angiography, IVUS, OCT, histology and micro CT (BVS program)  |
| 15:35-15:50   | <b>Renu Virmani</b>       | Biodegradable stents versus BMS: histopathology in perspective  |
| <b>TEA 16:00-16:45</b>  |                           |   |
| <b>GUIDED POSTER PRESENTATION</b>   |                           |   |
| <b>Biodegradable coatings: current experience and innovation in perspective</b> |                           |   |
| <b>Chairpersons: M.Joner J.P.Singh P.Buszman</b>                                |                           |   |
| 16:45-17:00   | <b>Nico Bruining</b>      | Technical challenges for long term sequential vessel evaluations using angiography, IVUS and OCT  |
| 17:10-17:26<br>17:10-17:18  | <b>Renu Virmani</b>       | Short and long-term experimental results using a combined –limus_biodegradable polymer coating technology (Biosensor's program)                 |
| 17:18-17:26   | <b>Giulio Stefanini</b>   | Clinical and imaging results of the Biomatrix™ program  |
| 17:36-17:52<br>17:36-17:44  | <b>Michael Joner</b>      | Short and long-term experimental results using a novel biodegradable polymer coating technology (Biotronik program)                             |
| 17:44-17:52   | <b>Thomas Pilgrim</b>     | Novel stent platform with a hybrid coating: clinical outlook of the ORSIRO™ hybrid DES with bioabsorbable polymer coating and a passive coating |
| 18:02-18:18<br>18:02-18:10  | <b>Juan Granada</b>       | Vascular response (short and long term) to DES in the atherosclerotic and domestic pig models: Synergy™-Promus_Element™-BMS (BSC program)       |
| 18:10-18:18   | <b>Juan Granada</b>       | Clinical results and program  |
| 18:28-18:44<br>18:28-18:36  | <b>Krzysztof Milewski</b> | Short and mid-term experimental results using a different biodegradable polymer/drug coating combinations (Balton program)                      |
| 18:36-18:44   | <b>Pawel Buszman</b>      | Clinical and imaging results of the LUC-Chopin <sup>2</sup> and Carlo – a biodegradable polymer coated paclitaxel and                           |

|                                |                        |   |
|--------------------------------|------------------------|---|
|                                |                        | everolimus eluting stents (Balton program)  |
| 18:54-19:10<br>18:54-19:02     | <b>Eric Ligtenberg</b> | Combo - A Combination Sirolimus Eluting Anti-CD34 Antibody Coated Stent: Technology and Development (Orbus program)       |
| 19:02-19:10                    | <b>Ulf Landmesser</b>  | Clinical and OCT results from a randomized trial Xience vs Combo (Orbus program)  |
| 19:20-19:35                    | <b>Renu Virmani</b>    | Longterm histo-pathological results in human using BMS and stable polymers: Can we speculate for biodegradable polymers ? |
| <b>SOCIAL EVENT from 19:45</b> |                        |   |

## Saturday 4<sup>th</sup> February 2012 (morning)

| Time  | Speaker                  | Title  |
|---|--------------------------|--|
| <b>Prevention of restenosis: Novelties I: Drug Eluting Balloon (DEB) or Drug Coated Balloon (DCB)</b> |                          |  |
| <b>Chairpersons: W.Wijns B.Scheller H.VanBeusekom</b>   |                          |  |
| 08:00-08:15   | <b>Renu Virmani</b>      | Coronary arteries versus peripheral arteries: what makes them different?                                       |
| 08:25-08:40   | <b>Bruno Scheller</b>    | Drug and excipient modulations and their impact on tissular kinetic  |
| 08:50-09:06   | <b>Rembert Pogge</b>     | Technical part: device description (Eurocor program)   |
| 08:50-08:56   |                          |  |
| 08:56-09:06   | <b>Mariann Gyöngyösi</b> | Biological response: Experimental and clinical results   |
| 09:15-09:31   | <b>Greg Kaluza</b>       | Technical part: Paccocath <sup>TM</sup> device evolution (Medrad program)                                      |
| 09:15-09:21   |                          |  |
| 09:21-09:31   | <b>Juan Granada</b>      | Biological response: Experimental and clinical results   |
| 09:40-09:56   | <b>Bob Melder</b>        | Technical description of the In Pact <sup>TM</sup> device and experimental results (Medtronic-Invatec program) |
| 09:40-09:46   |                          |  |
| 09:46-09:56   | <b>Bruno Scheller</b>    | Clinical results using the In Pact <sup>TM</sup> device  |
| 10:05-10:21   | <b>Andreas Hofmann</b>   | Technical part: Pantera Lux <sup>TM</sup> device (Biotronik program)   |
| 10:05-10:11   |                          |  |
| 10:11-10:21   | <b>Marcus Wiemer</b>     | Clinical results using the Lux <sup>TM</sup> technology  |
| <b>COFFEE 10:30-11:00</b>   |                          |  |

## Saturday 4<sup>th</sup> February 2012 (morning)

| Time   | Speaker                  | Title   |
|--|--------------------------|---|
| <b>COFFEE 10:30-11:00</b>  |                          |   |
| <b>Prevention of restenosis: Novelties II : new viewpoints – new fields of application – novel devices</b> |                          |   |
| <b>Chairpersons: E.Camenzind J.Granada F.Prati D.Locca</b>   |                          |   |
| 11:00-11:11  | <b>Christopher Owens</b> | The adventitia as a drug delivery target for PAD: preclinical and early phase clinical studies  |
| 11:19-11:30  | <b>Lewis Schwartz</b>    | Biodegradable stent for peripheral use: BVS-Absorb for superficial femoral artery (SFA) and below the knee (BTK) (Abbott)                                     |
| 11:38-11:49  | <b>Keith Faucher</b>     | An omega-3 derived bioabsorbable coating: evaluation of the fate of drug&coating, experimental results and clinical data (Atrium program)                     |
| 11:57-12:08  | <b>John Shulze</b>       | No-carrier coating: the Freedom™ program: experimental work and first clinical results (Biosensors program)   |
| 12:16-12:27  | <b>Robert Byrne</b>      | No-carrier coating: from the experimental work to the lessons of ISAR-TEST (Translumina program)  |
| 12:35-12:46  | <b>Enrico Pasquino</b>   | No-carrier coating: CID preclinical in vivo assessment and clinical program of CRE8™ stent - a new generation polymer free DES with Amphilimus™ (CID program) |
| 12:54-13:05  | <b>Cy Wilcox</b>         | No-carrier coating: Medtronic™ polymer free DES development - drug filled stent (Medtronic program)   |
| 13:13-13:28  | <b>Gabriel Steg</b>      | Clinical trial design: surrogated endpoints vs clinical endpoints in device trials  |
|  | Edoardo Camenzind        | Closing remarks   |
| <b>Farewell LUNCH 13.40-</b>   |                          |   |